Anti-Spike-RBD Human mAb
human monoclonal antibody against Spike protein receptor binding domain
Store at -20℃. Avoid freeze / thaw cycles.
exhibites high blocking activity against the SARS-COV-2 S1-RBD protein binding to the receptor of ACE2, and the FACS blocking activity is 0.89 nM.
FACS binding test of anti-Spike-RBD mAb and spike-RBD protein using ACE2 expressing Vero E6 cells
Blocking the binding of S1 protein and ACE2 protein is the main proposed mechanism of action for a SARS-COV-2 drug. The Anti-S1-RBD human antibody (Cat#: 166654) exhibites high blocking activity against the SARS-COV-2 S1-RBD protein binding to the receptor of ACE2, and the FACS blocking activity is 0.89 nM.
The S protein of the SARS-COV-2 binds to the receptor of ACE2 protein on cell membrane, and then infects human respiratory epithelial cells. The observation under electron microscope confirmed the molecular mechanism of the infection. The specific binding to the receptor of ACE2 molecule is the receptor binding domain (RBD)located on the S1 Subunit of the S protein.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"